{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 27 February 2006\line \line {\b Roche 
raises dividend by 25 percent} \line \line Annual General Meeting approves Annual 
Report and financial statements for 2005 and elects Beatrice Weder di Mauro to Board of Directors\line \line Roche\u8217?s 
Annual General Meeting (AGM), which was held today in Basel, approved all of the Board of Directors\u8217? 
proposals. The 632 shareholders in attendance, representing 144,869,427, or 90.54%, of a total of 160,000,000 
bearer shares, approved the 2005 Annual Report and financial statements. They also authorised a 25% 
increase in the gross dividend to 2.50 Swiss francs per share and non-voting equity security, the nineteenth 
dividend increase in as many years. The Swiss professor of economics Beatrice Weder di Mauro, who works 
in Germany, was elected to the Board of Directors. The AGM re-elected DeAnne Julius, Peter Brabeck-Letmathe 
and Horst Teltschik to the Board.\line \line In his address to shareholders, Chairman 
and CEO Franz B. Humer summed up the year as follows: \u8216?2005 was an excellent year for Roche. The Pharmaceuticals 
Division achieved its best result ever and Diagnostics showed a solid performance, leading to record 
sales and operating profit on a Group level. With the introduction of many novel diagnostics and life-saving 
drugs, and a great effort to increase the availability of Tamiflu, we again created sustainable value.\u8217?\line \line Apart 
from the 2005 results, Roche\u8217?s AGM focused on the efforts under way to prepare for a potential avian 
influenza pandemic and Roche\u8217?s role in those efforts, including the successful push to increase production 
of the anti-influenza drug Tamiflu. Jan van Koeveringe, Head of Pharma Global Technical Operations, 
stressed that \u8216?the threat of a human influenza pandemic poses a very special challenge for Roche, because 
our drug Tamiflu is one important element of pandemic preparedness. All the discussion about avian influenza 
and Tamiflu serves as a reminder of how closely interconnected healthcare innovation and corporate social 
responsibility are. We have taken targeted action to fulfil that responsibility. Even before governments 
began stockpiling Tamiflu, we initiated a massive increase in production capacity for the drug at our 
own risk. By the end of 2006 Roche will be capable of producing over 300 million packs of Tamiflu a 
year \u8212? which is roughly comparable to total production capacity in the influenza vaccine sector and 
more than we currently have orders for. In addition, we have significantly reduced the price on deliveries 
for government pandemic use and have granted sub-licenses to companies in China and India.\u8217?\line \line Following 
the AGM, the Roche Board of Directors reconstituted itself. Andr\u233? Hoffmann was named to succeed departing 
director Rolf H\u228?nggi as one of the Board\u8217?s Vice-Chairmen. There were also changes in the Board committees. 
The former Finance & Investment and Audit & Corporate Governance Committees were reconstituted 
and renamed the Audit Committee and Sustainability & Corporate Governance Committee. Both new committees 
are composed entirely of independent, non-executive directors, as is the Board\u8217?s Remuneration Committee. 
Andreas Oeri was chosen to chair the Sustainability & Corporate Governance Committee, and the Audit 
Committee will be chaired by DeAnne Julius.\line \line {\b About Roche} \line Headquartered 
in Basel, Switzerland, Roche is one of the world\u8217?s leading research-focused healthcare groups in the 
fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the 
early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range 
of fronts to improving people\u8217?s health and quality of life. Roche is a world leader in diagnostics, 
the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2005 
sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, while the Diagnostics Division 
posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has 
R&D agreements and strategic alliances with numerous partners, including majority ownership interests 
in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at 
www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All trademarks used 
or mentioned in this release are protected by law.\par}\line \line \line {\b Additional 
information} \line - Annual Report 2005\line - Roche 
Board of Directors\line \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}